Clinical Trials · NCT05938712
The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- University Health Network, Toronto
- Enrollment
- 20
- Start date
- Oct 2023
- Locations
- 1 site, Canada
- Primary endpoint
- Proximal tubular natriuresis with combination therapy